AMENDMENTS TO THE SPECIFICATION

Please replace paragraph [0048] with the following rewritten paragraph:

-- [0048] In some embodiments, a KLH conjugated TSA ~~(for example of FIG. 1 or FIG. 2)~~ is used to immunize XenoMouse® mice, available from Abgenix (e.g., Mendez et al. Nat. Genet. February 1997;15(2):146-56 and U.S. patent application Ser. No. 08/464,584, filed Jun. 5, 1995, Ser. No. 08/463,191, filed Jun. 5, 1995, Ser. No. 08/462,837, filed Jun. 5, 1995, Ser. No. 08/486,853, filed Jun. 5, 1995, Ser. No. 08/486,859, filed Jun. 5, 1995, and Ser. No. 08/759,620, filed Dec. 3, 1996 and U.S. Pat. Nos. 5,939,598, 6,075,181, 6,114,598, 6,150,584, 6,162,963, 6,235,883 and 6,673,986, 6,682,736, 6,713,610, and Japanese Patent Nos. 3 068 180 B2, 3 068 506 B2, and 3 068 507 B2 and European Patent No., EP 0 463 151 B1, grant published June 12, 1996, International Patent Application No., WO 94/02602, published Feb. 3, 1994, International Patent Application No., WO 96/34096, published October 31, 1996, WO 98/24893, published June 11, 1998, WO 00/76310, published December 21, 2000. The disclosures of each of the above-cited patents, applications, and references are hereby incorporated by reference in their entirety). Immunization can be accomplished using standard techniques and protocols. Immune response in the animals to the TSA can be measured, for example through measuring serum titers of anti-TSA antibodies. When desired levels of immune response are achieved, mice are sacrificed and B cells recovered which can be utilized to generate hybridomas, using standard protocols and techniques, or used directly to identify B cells producing antibodies of the desired function. Further techniques for generating antibodies by the use of B cells are discussed in U.S. Pat. No. 5,627,052 (Schrader) and Babcook et al. Proc Natl Acad Sci USA. Jul. 23, 1996;93(15):7843-8, which include techniques and products which are sometimes referred to as Xenomax® Both references are hereby incorporated by reference in their entireties. --